XTNT|EPS $0.00 vs $0.00 est|Rev $32.4M vs $30.8M est (+5.2%)|Net Income $57,000Xtant Medical Holdings, Inc. delivered a revenue beat in its fourth quarter, surpassing analyst expectations while reaching breakeven on the bottom line. The medical device company posted revenue of $32.4M, exceeding Wall Street’s $30.8M forecast by 5.2%.
The company reported diluted earnings of $0.00 per share, matching the $0.00 consensus estimate based on estimates from 1 analyst. Bottom-line profit came in at $57,000. The performance marked a significant turnaround from the prior year, with EPS moving up 100.0% from the -$0.02 posted in Q4 2024.
Revenue of $32.4M was up 3% year-over-year from the $31.5M recorded in Q4 2024. The modest top-line growth reflects the company’s continued progress in the competitive medical device sector, where Xtant Medical competes with orthopedic and spinal implant products.
Wall Street maintains a generally optimistic view on the stock, with consensus standing at 4 buy, 1 hold, and 0 sell ratings. The company’s ability to swing from a year-ago loss to profitability while growing its revenue base suggests improving operational efficiency in its medical device business.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.